Virus – Talk Bio

JPM26 Day 3: Sanofi CEO on RSV Scrutiny and Regeneron Dupixent Defense

21 hours ago talkbio0Tagged Beyfortus, Dupixent, JPM26, Paul Hudson, Regeneron, Respiratory syncytial virus, sanofi, United States Food and Drug Administration, Vaccines

JPM26; Sanofi; RSV; Beyfortus; Paul Hudson; FDA; vaccines; Dupixent; Regeneron

Just – Evotec Biologics Receives Gates Foundation Grant for AI-Driven Optimization of Monoclonal Antibody Developability

1 week ago talkbio0Tagged AI-driven, biotherapeutics, Country, developability, Drug Kinetics, Evotec SE, Financial cost, funding grant, Gates Foundation * *, Global Health, HIV, Immunogenicity (package insert), J.MD, low, Malaria, manufacturability, Manufactured Supplies, middle-income, Monoclonal Antibodies, Optimization, Platform, Respiratory syncytial virus, Stable status, Titer

Evotec SE; Gates Foundation; grant; J.MD; J.DESIGN platform; AI-driven optimization; monoclonal antibodies; biotherapeutics; developability; manufacturability; stability; immunogenicity; pharmacokinetics; titer; cost of goods; global health; affordable access; low- and middle-income countries; RSV; malaria; HIV

Oncolytics Biotech Expands GI Tumor Scientific Advisory Board with Eileen O’Reilly, Neil Segal, and Van Morris

1 week ago talkbio0Tagged biotech, Colorectal Carcinoma, Gastrointestinal Neoplasms, GI oncology, Malignant neoplasm of anus, Neil Segal, Oncolytics, Pancreatic carcinoma, pelareorep, platform immunotherapy * *, Scientific Advisory Board, Van Morris

Oncolytics Biotech; gastrointestinal tumor; Scientific Advisory Board; Neil Segal; Van Morris; pelareorep; pancreatic cancer; colorectal cancer; anal cancer; GI oncology; platform immunotherapy

Trump Administration Overhauls Childhood Vaccine Schedule, Reducing Recommendations and Sparking Industry Backlash

1 week ago talkbio0Tagged Childhood Vaccines, Gardasil, human papillomavirus, public health debate, RFK Kennedy, Trump administration, vaccine schedule

vaccine schedule; childhood vaccines; Trump administration; RFK Kennedy; Gardasil HPV; public health debate

US Commits $480-487 Million in Health Funding to Ivory Coast Under ‘America First’ Health Strategy

2 weeks ago talkbio0Tagged Americas, COAST, deals, Funding, global health security, Health, HIV, Ivory, Malaria, Tuberculosis, U.S.

US Ivory Coast health agreement; America First health deals; $487 million funding; HIV malaria tuberculosis; global health security

Updated Efficacy Data of Ivonescimab Plus Chemotherapy as First-Line Treatment for TNBC at ESMO IO 2025

1 month ago talkbio0Tagged AK112 - 308, Breakthrough Therapy Designation, Combined, Complex partial seizures, disease control rate, ESMO IO, First line treatment, Frequency of Responses, HARMONi-BC1, Ivonescimab, PD-1/VEGF bispecific antibody, PD-L1, Pharmacotherapy, Phase 2 Clinical Trials, Progression-Free Survival, safety profile, Subgroup A Nepoviruses, TNBC, Triple Negative Breast Neoplasms, Yidafan

ivonescimab; Yidafan; PD-1/VEGF bispecific antibody; triple-negative breast cancer; TNBC; first-line treatment; ESMO IO 2025; Phase II trial; chemotherapy combination; objective response rate; progression-free survival; disease control rate; PD-L1 CPS subgroups; safety profile; Breakthrough Therapy Designation; HARMONi-BC1; AK112-308

FDA reviews safety of approved RSV antibodies for infants

1 month ago talkbio0Tagged AstraZeneca, Beyfortus, Infant, Merck, nirsevimab, palivizumab, Respiratory syncytial virus, RSV antibodies, safety review, sanofi, United States Food and Drug Administration

FDA; RSV; nirsevimab; Beyfortus; palivizumab; RSV antibodies; infant safety review; Sanofi; AstraZeneca; Merck; respiratory syncytial virus

Co-Diagnostics Initiates Clinical Evaluations for Upper Respiratory Multiplex Point-of-Care Test on Co-Dx PCR Platform to Support Submission to the U.S. FDA

2 months ago talkbio0Tagged Clinical Evaluations, Co-Diagnostics, Co-Dx PCR platform, COVID19 (disease), Flu A/B, multiplex test, point-of-care, regulatory submission, Respiratory syncytial virus, United States Food and Drug Administration

Co-Diagnostics; clinical evaluations; multiplex test; point-of-care; Co-Dx PCR Platform; FDA 510(k); Flu A/B; COVID-19; RSV; regulatory submission

Sandoz Launches Tyruko (Natalizumab-Sztn), First Tysabri Biosimilar, in US After JCV Assay Delays

2 months ago talkbio0Tagged Approved, Biological Assay, Biosimilars, JC Virus, JCV, Leukoencephalopathy, Progressive Multifocal, Multiple Sclerosis, Polpharma Biologics, Progressive, sandoz, Tyruko, Tysabri, United States Food and Drug Administration

Sandoz; Tyruko; Tysabri biosimilar; natalizumab-sztn; multiple sclerosis (MS); biosimilar launch; JCV assay; progressive multifocal leukoencephalopathy (PML); FDA approval; Polpharma Biologics

AviadoBio Secures Option to UgeneX’s UGX-202 Gene Therapy for Retinal Disease

3 months ago talkbio0Tagged AviadoBio, Clinical Development, Dependovirus, gene therapy, Optogenetics, Retinal Diseases, Retinitis Pigmentosa, UGX-202

AviadoBio; UgeneX Therapeutics; UGX-202; retinitis pigmentosa; gene therapy; optogenetics; adeno-associated virus (AAV); exclusive option; retinal disease; clinical development